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Background: The majority of nursing home residents with dementia experience behavioural and psychological
symptoms like apathy, agitation, and anxiety. According to analyses of prescription prevalence in Germany,
antipsychotic drugs are regularly prescribed as first-line treatment of neuropsychiatric symptoms in persons
with dementia, although guidelines clearly prioritise non-pharmacological interventions. Frequently, antipsychotic
drugs are prescribed for inappropriate reasons and for too long without regular reviewing. The use of antipsychotics is
associated with adverse events like increased risk of falling, stroke, and mortality. The aim of the study is to investigate
whether a person-centred care approach, successfully evaluated in nursing homes in the United Kingdom, can
be implemented in German nursing homes and, in comparison with a control group, can result in a clinically relevant
reduction of the proportion of residents with antipsychotic prescriptions.
Methods/design: The study is a cluster-randomised controlled trial comparing an intervention group (two-day initial
training on person-centred care and ongoing training and support programme) with a control group. Both study
groups will receive, as optimised usual care, a medication review by an experienced psychiatrist/geriatrician providing
feedback to the prescribing physician. Overall, 36 nursing homes in East, North, and West Germany will be randomised.
The primary outcome is the proportion of residents receiving at least one antipsychotic prescription (long-term
medication) after 12 months of follow-up. Secondary outcomes are residents’ quality of life, agitated behaviour,
as well as safety parameters like falls and fall-related medical attention. A health economic evaluation and a process
evaluation will be performed alongside the study.
Discussion: To improve care, a reduction of the current high prescription rate of antipsychotics in nursing homes by
the intervention programme is expected.
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Prescription rates of antipsychotic drugs for residents in
German nursing homes are considerably high [1] and
have not changed for years [2–5]. Recent data show that
antipsychotics are prescribed for almost 30 % of German
nursing home residents [1]. Studies indicate that up to
two thirds of antipsychotics for residents are prescribed
for inappropriate reasons [6]. Furthermore, antipsychotics
are often prescribed for too long without carrying out a
regular review [7]. Both long-term and short-term use of
antipsychotics increase mortality compared to non-users
[8–10], with cardiac death and infections being the main
causes. All antipsychotics are associated with an increased
risk of stroke, and the risk might even be higher in pa-
tients/residents receiving atypical antipsychotics compared
to those receiving conventional antipsychotics [11]. Ad-
verse effects also include sedation, dizziness and increased
risk of falling and fall-related injuries, tremor and rigidity
[12–16], worsening of cognitive function [17], and other
effects which are most likely to result in reduced quality of
life (QoL) and well-being as well as withdrawal from social
life and participation.
Antipsychotics are mostly prescribed to control behav-
ioural and psychological symptoms of dementia (BPSD) [1].
BPSD are a meaningful clinical target for interventions
since restlessness, agitation, aggression, delusions, apathy,
disinhibition, and hallucinations are highly prevalent among
residents with dementia [18] and pose a major challenge
for nursing home staff, frequently leading to distress in
patients and carers [19]. The majority of residents with
dementia experience BPSD at some point of the dementia
trajectory, even in early stages of dementia [20, 21]. These
symptoms are highly consistent over the course of five
years with a tendency to increase over time [22]. Inter-
national and national clinical practice guidelines recom-
mend that psychological and environmental approaches
should be the first treatment option of BPSD [23, 24],
since non-pharmacological interventions individually
tailored to the person with dementia are effective [25].
To meet individual needs of residents and improve
their QoL, the person-centred care (PCC) approach seems
to be appropriate. One highly recognised concept has been
introduced by Kitwood [26, 27]. The components of this
concept are to regard personhood in people with dementia
as increasingly concealed rather than lost, to acknowledge
the personhood of each individual in all aspects of care,
to personalise care and environment, to offer shared
decision-making, to interpret behaviour from the viewpoint
of the person with dementia, and to prioritise the relation-
ship as much as the care tasks [28]. Personalised activities
were effective at reducing agitation in care home residents
[29, 30]. Drugs should only be used as a last resort and
should be discontinued immediately after symptoms vanish
or improve over a period of 3 months [31, 32]. Thus,nursing homes are urgently requested to strive for a de-
crease of antipsychotics prescribed for BPSD in favour
of non-pharmacological treatment [1].
Systematic reviews [33, 34] indicate that training and
support for care home staff reduce prescription of anti-
psychotics in residents with dementia and can be viable
alternatives for managing BPSD. The most recent and
most rigorous trial [35], which is the basis for the
present study, demonstrates the strongest effect without
adverse events. In addition to a PCC approach, a review
of drugs was conducted by an old-age psychiatrist taking
part in this study [35]. After 12 months, the proportion
of residents receiving antipsychotics in the intervention
homes (23.0 %) was significantly lower than in the control
homes (42.1 %) with an average reduction in antipsychotic
use of 19.1 % (95 % confidence interval 0.5 to 37.7 %) [35].
Summarising, to evaluate the intervention programme
by Fossey et al. [35] seems to be the most promising ap-
proach, although the programme requires a thorough adap-
tation to the German long-term care and health system.
Trial objective
The aim of our study is to investigate whether a PCC ap-
proach, successfully evaluated in nursing homes in the
United Kingdom [35], can be implemented in German
nursing homes and, in comparison with a control group,
can result in a clinically relevant reduction of the pro-
portion of residents with antipsychotic prescriptions.
Our primary outcome is the proportion of residents
with at least one antipsychotic prescription (long-term
medication) after 12 months of follow-up.
A further aim is to investigate whether QoL will im-
prove or at least be unchanged as shown by Fossey
et al. [35]. In accordance with the results of the primary
efficacy study and a Cochrane review [33], we assume
that the intervention is not only effective but also does
not harm the residents, i.e. dementia-related BPSD will
not worsen in the intervention group, and prescription
rates of other psychotropic medication as well as the
application of physical restraints will not increase.
Therefore, the following secondary outcomes will be
evaluated (at 12 months):
 Presence of agitated behaviour,
 Residents’ QoL,
 Median daily dose of antipsychotics in
chlorpromazine equivalents,
 Proportion of residents with dementia with
antipsychotic prescription,
 Proportion of residents without dementia with
antipsychotic prescription,
 Prescription prevalence of other psychotropic drugs
(antidepressants, anxiolytic and hypnotic drugs,
acetyl-cholinesterase inhibitors),
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fractures and sutures, fall-related medical attention
as well as the proportion of residents with at least
one physical restraint (bilateral bedrails, belts,
fixed tables, and other measures limiting free body
movement), and the number and types of physical
restraints.
Additionally, a health economic evaluation will be
conducted alongside the study. A process evaluation will
also be performed, aiming to comprehensively analyse
the underlying processes as well as the barriers and facil-
itators of the implementation of this multicomponent
intervention, giving special focus to regional differences.
The programme will be implemented in nursing homes
in East, North, and West Germany in order to evaluate
its supra-regional generalisability.Recruitment of nursing homes and as
in Halle (Saale), Lübeck & W
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Fig. 1 Flow chart of EPCentCareMethods/design
Study design
The study is a multicentre, cluster-randomised controlled,
pragmatic trial using parallel groups with a 1:1 randomisa-
tion (on cluster level) and 12 months of follow-up. Figure 1
displays the study flow.
The optimised usual care for both study groups will be
a medication review by an experienced geriatrician and/or
psychiatrist with feedback to the prescribing physician. All
the general practitioners (GPs), neurologists, and psychia-
trists for the study participants will be offered 2 h of
continuing medical education on the subject.
For the nursing homes in the intervention group, an
educational intervention on PCC and a continuous
supervision programme will be conducted. The control
group will receive no further intervention other than the
optimised usual care.sessment for eligibility 
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Inclusion and exclusion criteria
The study will be performed in 36 nursing homes in the
cities/catchment areas of Halle (Saale), Lübeck, and Witten.
Individual nursing homes or units working independently
within a large nursing home will be defined as a cluster.
Inclusion criteria will be nursing homes with at least
50 residents; each participating institution must have
sufficient resources (staff, time) to conduct the study,
and no special “dementia projects” or other activities po-
tentially influencing the intervention will be allowed.
All residents within a cluster will be eligible to partici-
pate in the study. Exclusion criteria at the individual
level will be:
(a)Temporary stay in respite care and/or
(b)Primary diagnosis of schizophrenia, or bipolar
disorder.Recruitment of study centres and study participants
In each study region, nursing homes will be randomly
selected from the respective nursing home register.
These facilities will be invited to take part in the study
either via postal mail or telephone. The study will be
presented to the directors of the nursing homes, who
will decide whether their home will participate. A resident
representative or, if not available, a residents’ advocate will
be involved in all activities and decisions.
All eligible residents or their proxies or legal guardians
will receive oral and written information about the aims
and purpose of the study as well as all the information
required according to good clinical practice (GCP) rules
to create informed consent. Questions and additional
information about the study will be available from the
project staff of the respective study centre, either in
person or by phone. Consent may be withdrawn for
any reason at any time and without notice, without in-
curring any disadvantages for the residents. All resi-
dents who move into the nursing home during the
study period will be eligible to participate too and will
be asked for consent.
A total of four nursing homes (two facilities each in
the intervention group and in the control group) will
take part in a controlled pilot study at the study centre
in Halle (Saale). The study will be implemented respect-
ively in recruiting phases of four nursing homes per study
site with a time shift of 2 months. The data collection will
end in the last quarter of 2016.The EPCentCare intervention
The study intervention will consist of four components,
depending on group assignment (see Table 1).Continuing medical education provided for prescribing
physicians (intervention and control group)
In Germany, residents of nursing homes have a free
choice of medical practitioner. Therefore, the continuing
medical education (CME) will address all physicians who
are involved in the care of the participating residents of
both study groups. The GPs, neurologists, psychiatrists,
and geriatricians will take part in a 2-h workshop.
Topics of the training will be diagnostics and care for
people with dementia as well as non-pharmacological
and pharmacological treatment options for people with
BPSD. The education content will be prepared in ac-
cordance with German national evidence-based clinical
practice guidelines [23, 36]. Parts of the educational
material have been used successfully in former studies
[37, 38]. The focus will be on psychotropic medications
and antipsychotics (e.g. guideline-based recommendations
for use, adverse effects/risks, and contraindications). Fur-
thermore, we will present and discuss options for optimis-
ing treatment and care for people with BPSD in nursing
homes using the example of EPCentCare. All participants
will receive written information about the central aspects
of the training.
Physicians who do not attend the workshop, as well as
new physicians joining the project during the study
period, will receive written information on the workshop
topics. The workshop will be offered locally at the par-
ticipating universities.
Medication review (intervention and control group)
Residents of both study groups with an ongoing anti-
psychotic prescription will receive a medication review by
a consultant psychiatrist or geriatrician. The medication
review will be based on residents’ case files and communi-
cated as a written report including specific recommenda-
tions to the prescribing physicians.
The medication reviews will be carried out at base-
line and after 3, 6, and 9 months according to national
evidence-based clinical practice guidelines [23, 36],
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formation documents. The respective relevant data for
the psychiatrist/geriatrician will be pseudonymised. The
study coordination centre will ensure forwarding of the
reviews to the prescribing physicians.
Information event for the nursing home staff (only
intervention group)
All the staff in intervention group homes will receive
relevant information about the study in a 60-min pres-
entation. They will get particular information on the
topics “antipsychotics for people with BPSD” and “PCC
and non-pharmacological interventions”.
Training and support of “experts for person-centred care for
the elderly—EPA” (only intervention group)
Based on Fossey et al. [35, 40], selected staff from the
nursing homes in the intervention group will be trained
and instructed to work as “experts for person-centred
care (PCC) for the elderly (EPA)”. The responsibilities of
the EPA will be:
 Identifying organisational needs for change within
the institution and opportunities for developing
specific aspects of care
 Planning and supporting the implementation of PCC
in the nursing facility.
 Initiating discussions with colleagues about PCC
activities for specific residents.
 Discussion with colleagues about the medication
review or contacting the prescribing physician.
 Advice and support of colleagues as facilitator and
primary contact person for colleagues, relatives, and
physicians.
The training programme for the EPA will include a 2-
day initial workshop on PCC as well as continuous
training and support over the 12-month study period.
The workshop will take place on two consecutive days
at the respective study centre/university. An expert in
PCC will present the following content:
 Introduction to EPCentCare.
 Antipsychotics in people with BPSD: list of
medications, reasons for prescription, side effects, and
guideline-based recommendations for use [23, 36, 41].
 PCC on resident level: according to Kitwood [26, 27],
recognising individual residents’ needs and reasons for
behaviour [40], dealing with challenging behaviour
[25, 29, 40, 42, 43], and reflection of case examples.
 PCC on institutional level: assessing, supporting, and
managing development of PCC in a nursing home
[40, 41].
 Supervision/support programme [35].The trained experts will be supported during the inter-
vention period by a study nurse specialised in dementia
and PCC (continuous in-house training). The supervi-
sion may be carried out individually and/or in groups in
a minimum time frame of 3 to a maximum of 6 h per
month and nursing home. As part of the supervision,
the EPA will be supported in recognising residents’
needs [40] in implementing PCC plans, in promoting
the participation of the residents in activities, and possibly
in implementing environmental changes.Cluster-randomisation
The randomisation will be carried out on a cluster level.
The randomisation list will be computer-generated by an
independent external biometrician, who will be blinded to
the identity of the participating organisations and residents.
Nursing homes will be allocated to the intervention or con-
trol group using a balanced block randomisation, stratified
by the three regions Halle (Saale), Lübeck, and Witten as
well as the time point of the recruiting phase. Because of
the low number of homes per stratum (n = 4), no further
blocks within the strata are planned. This randomisation
list will contain pseudonymous identification numbers for
nursing homes and allocation of group A or B.
Parallel to this, responsible coordinators of the three
study centres will independently determine and document
the allocation (intervention group or control group) for
group A and group B at study begin, without informing
the external biometrician.
After completion of the baseline measurement of the
corresponding recruiting phase, an independent person
from the study centre in Lübeck will electronically (pass-
word-protected, encoded https portal) assign the random-
isation list and nursing home data for concealed allocation
[44] and will inform the nursing homes in written form.
After confirmation of group allocation by the nursing
homes, the assigning person will inform the coordinator of
the respective study centre about the allocation results.Blinding
Due to the nature of the intervention, blinding of the
nursing home staff and the field researchers will not be
possible. However, the biostatistician, who will not be in-
volved in conducting the study, will perform a step-wise
statistical analysis blinded towards the group allocation
of residents and clusters: (1) A blinded review of data
without the nursing home IDs and group allocation will
be carried out; depending on data structure, necessary
adaptations of statistical analysis procedure will be per-
formed. (2) Nursing home IDs and group allocation
(group A or group B) are added to the data; group specific
analyses will be carried out. (3) A or B will be unblinded
after completion of the final analysis.
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tion review are also blinded towards group allocation.
Additionally, research assistants assessing the primary
endpoint will be blinded towards group allocation. Data
entry will be carried out without knowledge about the
group allocation of the clusters.
Measures
Institutional level
The description of the participating nursing homes, data on
general characteristics, staff characteristics, characteristics
of living environment, and living and care concept accord-
ing to Palm et al. [45] will be gathered from the nursing
home director before randomisation. The proportion of eli-
gible residents receiving an antipsychotic prescription will
be recorded at baseline and after 12 months.
Resident level
Five measurement points are scheduled in the study:
baseline assessment and measurements after 3, 6, 9, and
12 months (see Table 2).
At baseline (t0), socio-demographic and clinical data
will be assessed from all included residents and will be
documented in a case report form (CRF).
Residents’ QoL will be measured at t0 and t4 using the
German version [46] of a QoL instrument which is also
suitable for residents with dementia. The validated in-
strument Quality of life-Alzheimer’s disease—QoL-AD
[47, 48] comprises 13 items with 4-point Likert scales
for self or proxy assessment (total score ranges from 13
to 52, higher scores mean higher QoL). Self-assessment
will be performed by short interviews with the residents;
proxy assessment will be conducted by nursing staff.
To determine a cut-off point for the QoL-AD self or
proxy assessment tool, the validated Dementia Screening
Scale (DSS) [49] will be used as a cognition test (internal
consistency: Cronbach’s alpha = 0.94). For this purpose,
nursing staff will have to evaluate different aspects of
cognitive function regarding seven items with 3-point
Likert scales in the domains “memory” and “orientation”
over the last 4 weeks (total score ranges from 0 to 14;
higher scores indicate more severe cognitive impairment).
As the test will be used to decide if a QoL-AD self-
assessment is feasible, we will use a cut-off point of >4
(specificity 88.8 %, sensitivity 84.2 %) [49].
Agitated behaviour as one aspect of BPSD will be
assessed with a German version [50] of the Cohen-Mans-
field Agitation Inventory (CMAI) [51–53] (measurement
points t0 and t4). The CMAI is a caregiver rating instru-
ment with good psychometric properties of the original
version [52] and will be performed by interviewing the
nursing staff. The scale consists of 25 items of agitated
behaviours, each rated on a 7-point scale of frequency
of occurrence over the last 2 weeks (total score rangesfrom 25 to 175, higher scores mean higher frequencies
of manifestation).
To analyse the proportion of residents receiving an
antipsychotic prescription, the median daily dose of anti-
psychotic drugs in chlorpromazine equivalents, and the
prescription prevalence of other psychotropic drugs, the
following data will be gathered: (1) prescriptions of antipsy-
chotics (long-term and pro re nata (PRN) medication) from
routine documentation at t1, t2, t3, and t4 retrospectively for
the last 3 months: registered trade name or agent, dose,
and prescription period; (2) current prescriptions of other
psychotropic drugs (long-term and PRN medication) from
routine documentation at the time point of t1, t2, t3, and t4:
registered trade name or agent, and dose.
Additionally, safety and/or adverse outcome parameters
like falls, fall-related fractures and sutures, fall-related med-
ical attention, as well as the number and types of physical
restraints [2] will be documented at t1, t2, t3, and t4 retro-
spectively for the last 3 months, using data extracted from
routine documentation.
Richter et al. Implementation Science  (2015) 10:82 Page 7 of 10New participants during the study period will be
assessed at the next measurement point after their
nursing home admission: socio-demographic and clinical
data, QoL and cognition (QoL-AD, DSS), and agitated
behaviour (CMAI) at this point will be regarded as
baseline data of the new participant. Medication data
and safety parameters since nursing home admission
will also be documented retrospectively.
Data for medication reviews
For residents with an antipsychotic prescription at the
point of measurement (t0 to t3), we will assess all anti-
psychotic prescriptions during the last 3 months and
provide the psychiatrist/geriatrician with this information
for the medication review.
All data for medication reviews are summarised in
Table 3.
Process evaluation
Since we will be investigating a complex intervention, a
detailed process evaluation is essential [54, 55]. Process
evaluation outcomes will be collected according to a
framework for cluster-randomised trials of complex
interventions suggested by Grant et al. [56]. Different
methods will be used for data collection alongside the
study: investigators’ documentation, questionnaires on
staff knowledge and self-efficacy, structured interviews,
and in-depth interviews with staff, residents, and their
relatives. A detailed protocol is under preparation.
Health economic evaluation
The objective of the economic evaluation is to estimate
the cost-effectiveness of the intervention in terms of
additional costs per additional resident not receiving an
antipsychotic prescription. The economic evaluation will
be performed from the perspective of the German social
insurance (statutory health insurance and long-term care
insurance). To this end, an incremental cost-effectiveness
ratio (ICER) will be calculated, i.e. the ratio of the differ-
ence in costs between intervention and control group di-
vided by the difference in the proportion of residents
without a psychotropic medication gained in each group.
A detailed description of the health economic evalu-
ation can be found in Additional file 1.
Sample size calculation
The primary endpoint of the study is the proportion of
residents with at least one antipsychotic prescription
after 12 months (t4). The following sample size estimation
was performed as described in Donner & Klar [57] for the
cluster-adjusted χ2-test. Based on recent prevalence data,
we expect a baseline prevalence of antipsychotic prescrip-
tion of 30 % [2]. Due to the measures of optimised usual
care in the control group and based on the study by Fosseyet al. [35], we expect the prevalence in the control group to
decline slightly to 26 % after 12 months. We expect a
relative risk reduction of approximately 50 % regarding
antipsychotic prescription in the intervention group.
Assuming a significance level of 5 % (α = 0.05), a two-
sided test for proportions, and an intra-class correlation
coefficient (ICCC) of 0.05, an average cluster size of 65
nursing home residents, 15 clusters are required per
group to detect a 12 % difference in proportions from
26 % of the control group at 12 months with 90 % power
(β = 0.10). Presuming that six nursing homes might drop
out, 36 clusters with a total of 2340 residents will be
needed.
We expect 25 % of residents with early study termin-
ation due to death or moving; the other 75 % of resi-
dents of the baseline population we expect to be still
living in the nursing home and to be available for the
12-month follow-up assessment. As the outcome, the
analyses will focus on the group of residents living in the
nursing homes after 12 months. Assuming that new resi-
dents will all be willing to participate in the study, this
will not affect the sample size.
Statistical analysis
No interim analysis will be performed. Analysis will be
based on the intention-to-treat principle. The analysis
will be done at the resident level.
For the primary outcome measure, i.e. the proportion
of residents with at least one antipsychotic prescription
after 12 months, proportions will be compared between
the intervention group and control group, using a two-
sided cluster-adjusted χ2-test at a level of significance
of α = 0.05 [57]. Corresponding cluster-adjusted 95 %
confidence intervals will be calculated. Furthermore, to
investigate the time course of the intervention effect, in-
cluding all the residents observed after 3, 6, 9, or 12 months,
drug prescriptions of antipsychotics per resident after 3, 6,
9, and 12 months will be analysed as a dependent variable
in a generalised linear mixed (logistic) model with the inter-
vention as a fixed effect, clusters as a random effect, and
using covariance patterns to adjust for repeated measure-
ment. This will be done as a secondary analysis.
For the secondary outcome measures, linear mixed
models or generalised linear mixed methods will be used,
adjusting for clusters by random effects. Subgroup analyses
using linear mixed models will be performed for gender
and cognitive status. The analysis of all secondary outcomes
is interpreted exploratively and not confirmatively.
A detailed description of the statistical analysis can be
found in Additional file 2.
Data management
Study data will be recorded, pseudonymised in paper
form in the nursing homes, and electronically stored





• Registered trade name or agent





PRN medication (antipsychotic drugs) • Registered trade name or agent
• Dosage form
• Number of received partial dose
• Suggested maximum dose
• Prescription period
• Prescribing physician
• Case of need
Further current long-term and
PRN medication
• Registered trade name or agent
• Dose
• Regimen
Medical carea • Psychopathological reports
• Number of physician contacts
(GP, neurologist, psychiatrist,
and geriatrician) over the last
three months and date of the
last visit
• Body weight: current and three
months before
• Intolerance of drugs
Neuropsychiatric symptomsa












Potential adverse effects of
antipsychotic drugsa (over the last
2 weeks)
• Pain












• Relevant clinical diagnoses
• Falls
aSource: routine documentation of residents
bSource: case report form
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(name, birthday, etc.) will be kept separately from the
study data. All participating nursing homes will also re-
ceive a pseudonymous identification number. Key lists
will be stored separately from the study data and will be
deleted after final validation of the analytical data set
and data freezing.
Data will be entered electronically at the study centre
in Lübeck. The data matrix will be based on the codebook
created prior to the study. The questionnaires will be read
electronically by a scanner-based software (TeleForm®).
During scanning and electronic recording, a plausibility
check will be performed. Written requests will follow in
the case of unclear data or lack of data. Unclearly placed
check marks and text fields will be checked and corrected
manually. To ensure data quality, important data (e.g.
antipsychotic prescription) will be checked by hand.
Changes and corrections to the database will be clearly
documented. After data freezing, no further data changes
will be possible. Data entry will be performed within
1 month after recording.Quality assurance
The study will be planned, implemented, and evaluated in
accordance with the principles of good clinical practice
(ICH-GCP) [58] and the Declaration of Helsinki [59].
A concordant study procedure in all three study centres
will be ensured by a central external audit. Data monitoring
will increase the credibility of the study and help to im-
prove data collection and archiving procedures. It will be
carried out according to a data-monitoring manual which
follows GCP and which has been developed and applied in
a former study [60].Dissemination policy
We plan to publish the study results in a peer-reviewed,
Medline-listed journal. All results will be reported referring
to this study protocol and to the CONSORT statement
extended to cluster-randomised trials [61] as well as to
CReDECI [62].
We will set up a German-language homepage for
reporting the study results and accessing all materials,
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of trial.
Ethical and legal considerations
This project has received ethical approval from the ethics
committee of the Medical Faculty, Martin Luther University
Halle-Wittenberg, Germany (no. 2014–101), as well as
from the ethics committees of the Universities of Lübeck
(no. 14–239) and Witten/Herdecke (no. 133/2014). All
ethics committees will be informed immediately about any
protocol amendments and serious or unexpected adverse
events as well as a premature end of the study.
Discussion
Based on previous study results [2, 35], we do not expect
any risks for the participating residents. The intervention
programme has been tested successfully in the United
Kingdom, and the discontinuation of antipsychotics showed
no negative consequences [35]. Systematic reviews support
only a short-term antipsychotic treatment, because of
the significant adverse effects and a lack of evidence for
prolonged prescription [17, 31]. We expect that the
intervention programme will reduce the current high
prescription rate of antipsychotics in nursing homes.
Trial status
The pilot phase of the study has been started.
Additional files
Additional file 1: Detailed description of the health economic
evaluation.
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